<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03199794</url>
  </required_header>
  <id_info>
    <org_study_id>241501</org_study_id>
    <nct_id>NCT03199794</nct_id>
  </id_info>
  <brief_title>Prospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice</brief_title>
  <official_title>Prospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxalta Innovations GmbH, now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study addresses the safety, utilisation and effectiveness of Obizur in the treatment of
      bleeding episodes in real-life clinical practice in Europe.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of AEs and SAEs including seriousness, severity and outcome</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>AE - adverse event, SAE - serious adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of AESIs including seriousness, severity, relationship to therapy, outcome, and treatment discontinuation</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Adverse Events of Special Interest (AESI) are as follows: hypersensitivity reactions, thromboembolic events and dose dispensing medication errors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of thromboembolic events</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Thromboembolic events include disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction and stroke.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of dose dispensing medication errors</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Dose dispensing medication erros include miscalculation of dose while prescribing (calculation of correct dose based on the participant's weight) or administration of the incorrect dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity; newly recognized anti-pFVIII inhibitor or increase in titre of anti-pFVIII inhibitors and evolution of titre over time</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obizur treatment regimen, as available</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>This may include details of the Obizur treatment regimen utilized, as available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other medication administered for haemostatic control, as available</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>This may include additional medications, treatments and procedures (other than Obizur) undertaken to control a bleeding episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall effectiveness assessment for resolution of bleeding</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Resolution of bleeding determined as either bleeding stopped or did not stop. If bleeding did not stop, a reason should be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose per infusion administered to achieve bleeding control, death or change in haemostatic treatment other than Obizur</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Bleeding control defined as all bleeding stopped.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusions administered to achieve bleeding control, death or change in haemostatic treatment other than Obizur</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Bleeding control defined as all bleeding stopped.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve bleeding control, death or change in haemostatic treatment other than Obizur</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Bleeding control defined as all bleeding stopped.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acquired Hemophilia A</condition>
  <arm_group>
    <arm_group_label>OBIZUR participants</arm_group_label>
    <description>Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OBIZUR</intervention_name>
    <description>Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.</description>
    <arm_group_label>OBIZUR participants</arm_group_label>
    <other_name>Recombinant pFVIII</other_name>
    <other_name>Porcine Sequence</other_name>
    <other_name>rpFVIII</other_name>
    <other_name>Antihemophilic Factor (Recombinant)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A participant with acquired hemophilia (AH) must be prescribed Obizur for the treatment of
        a bleeding episode by a physician, independent of and prior to the decision to enrol the
        participant in the study.
      </textblock>
    </study_pop>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult participant (or legal representative) is willing to provide informed consent

          -  Participant is being treated or was treated (treatment initiation within 30 days) with
             Obizur in routine clinical practice

        Exclusion Criteria:

          -  Participant has known anaphylactic reactions to the active substance, hamster protein
             or to any of the following excipients: Polysorbate 80; sodium chloride; calcium
             chloride dihydrate; sucrose; Tris Base; Tris HCl; Tri-sodium citrate dihydrate;
             sterilized water for injections

          -  Participant has participated in a clinical study involving a medicinal product or
             device within 30 days prior to enrollment or is scheduled to participate in another
             clinical study involving a medicinal product or device at study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lydia Abad Franch, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxalta now part of Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oliver Mauric</last_name>
    <email>oliver.mauric@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AKH - Medizinische Universit√§t Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

